If approved, Amgen and Allergan’s biosimilar – called ABP ... last month at a 10% discount to Roche’s US list price, initially only for Rituxan’s oncology indications as it has agreed ...
South Korea's Celltrion has already filed its rituximab biosimilar in Europe in November. Sandoz's biosimilar adds to a long list of biosimilars under review in Europe, including two versions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback